University of Cambridge spin-out, PredictImmune is developing pioneering tools to guide physicians in the treatment of patients with immune-mediated disease, through prediction of long-term clinical prognosis.
Founded in May 2017, the company is currently developing its first product, a prognostic biomarker test, to address inflammatory bowel disease (both Crohn’s and ulcerative colitis).
The technology, based on world-leading research emanating from the University of Cambridge, accurately identifies patients – at diagnosis – who are at risk of experiencing severe, relapsing disease and therefore likely to benefit from early biologics therapy.
Babraham-based PredictImmune raised £4.7m Series A funding in May 2017 led by Parkwalk Opportunities Fund with co-investment from Cambridge Enterprise and Wren Capital. It recently secured an additional £4.3 million investment from the Wellcome Trust to support a prospective multi-centre clinical trial of its prognostic biomarker test.
PredictImmune won Business Weekly’s Life Science Innovation (Best Product) Award in March 2019.
In May 2019, it was announced that PredIctImmune was developing a test that can reliably predict the future course of inflammatory bowel disease in individuals, transforming treatments for patients and paving the way for a personalised approach.
PredictImmune co-founder and head of the University of Cambridge’s Department of Medicine, Professor Ken Smith is leading a £4.2m trial to see whether using the biomarker to guide treatment at the time of diagnosis can lead to better outcomes for patients.
The test is supported by the University’s tech transfer arm, Cambridge Enterprise. Later this year, Professor Smith and his team are due to move into the new Cambridge Institute of Therapeutic Immunology and Infectious Disease, to be based in the Jeffrey Cheah Biomedical Centre on the Cambridge Biomedical Campus.
CEO Paul Kinnon has held senior positions with Transgenomic, ZyGEM Corp., Life Technologies (now ThermoFisher), Guava Technologies and Cellomics, generating more than $60m in funding while creating global partnerships and increasing shareholder return.